All In Biotech

Drug Trial Radar · NCT03678753

Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in PGTC Seizures

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Cenobamate Adjunctive Therapy in Subjects With PGTC Seizures

Last checked: Nov 19, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 169 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

169

Actual

Start

Oct 3, 2018

Primary completion

May 26, 2025

Study completion May 26, 2025

Sponsor

Lead sponsor
SK Life Science, Inc.Industry
Sponsor type
Industry
First posted
Sep 20, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is intended to study the safety and effectiveness of an new anti-epileptic drug (AED) on Primary Generalized Tonic-Clonic (PGTC) Seizures. Eligible Subjects, adults and adolescents, will continue to take their usual AEDs and receive either cenobamate or placebo. Subjects will have a 50% chance or receiving cenobamate or placebo (sugar pill). Subjects will initially receive 12.5 mg of cenobamate or placebo (study drug) and increase the dose every two weeks until they reach a target dose of 200 mg. Subjects will take study drug at approximately the same time in the morning (once a day) with or without food. If tolerability issues arise, dosing can be changed to evening. Also, once a subject reaches 200 mg, the dose can be decreased one time to 150 mg, if necessary. The treatment period is 22 weeks and there is a 3 week follow up period, which includes a one week decrease in study drug to 100 mg prior to stopping. Adolescents will follow the same every two week regimen and receive cenobamate as an oral suspension based on weight. Subjects who complete may be eligible for an extension study and will not have to complete the follow up period. Subjects will track their seizure types and frequency in a diary throughout the study.

Conditions

  • Primary Generalized Epilepsy

Interventions

  • CenobamateDrug

    12.5 mg tablet, 25 mg tablet, 50 mg tablet, 100 mg tablets, 150 mg tablets, 200 mg tablets. Adolescents will follow the same every two week regimen and receive cenobamate as an oral suspension based on weight.

  • PlaceboDrug

    Matching Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. USA and Rest of World (RoW): Percent Change in PGTC Seizure Frequency Per 28 Days During the Double-blind Treatment Period Relative to Baseline.Time frame: Baseline and 22-week Double-blind Treatment Period.
  2. Europe, South Africa, Australia, and New Zealand: 50% Responder Rate for PGTC Seizures During the Maintenance Phase Relative to Baseline.Time frame: Baseline and 12-week Maintenance Phase.

Locations

116 sites in 12 countries. Site status is shown where the registry gives one.

  • Phoenix Children's Hospital

    Phoenix, Arizona

  • Center for Neurosciences

    Tuscon, Arizona

  • Neuro Pain Medical Center

    Fresno, California

  • Colorado Springs Neurological Associates

    Colorado Springs, Colorado

  • Children's Hospital of Colorado

    Grand Junction, Colorado

  • Brainstorm Research

    Miami, Florida

  • Florida Hospital Medical Group

    Orlando, Florida

  • University of South Florida

    Tampa, Florida

  • Clinical Integrative Research Center of Atlanta, CIRCA

    Atlanta, Georgia

  • Children's Healthcare of Atlanta

    Atlanta, Georgia

  • Hawaii Pacific Neuroscience

    Honolulu, Hawaii

  • Consultants in Epilepsy and Neurology

    Boise, Idaho

  • Rush University

    Chicago, Illinois

  • Indiana University

    Indianapolis, Indiana

  • PMG Research of McFarland Clinic

    Ames, Iowa

  • University of Kentucky

    Lexington, Kentucky

  • Maine Medical Center

    Scarborough, Maine

  • Mid-Atlantic Epilepsy and Sleep Center

    Bethesda, Maryland

  • Michigan State University

    East Lansing, Michigan

  • Minneapolis Clinic of Neurology Golden Valley

    Golden Valley, Minnesota

  • Mayo Clinic - Rochester

    Rochester, Minnesota

  • University of Missouri Health Care

    Columbia, Missouri

  • JFK Medical Center- The Neuroscience Institute

    Edison, New Jersey

  • Northeast Regional Epilepsy Group

    Hackensack, New Jersey

  • Saint Peter's University Hospital

    New Brunswick, New Jersey

  • New York Presbyterian Hospital

    Brooklyn, New York

  • UBMD Neurology

    Buffalo, New York

  • Five Towns Neuroscience Research

    Woodmere, New York

  • Duke University Children's Health Center

    Durham, North Carolina

  • Ohio Health Research and Innovation Institute

    Columbus, Ohio

  • University of Toledo

    Toledo, Ohio

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • Temple University Lewis Katz School of Medicine

    Philadelphia, Pennsylvania

  • LeBonheur Children's Medical Center

    Memphis, Tennessee

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Child Neurology Consultants of Austin

    Austin, Texas

  • ANRC Research

    El Paso, Texas

  • Baylor College of Medicine

    Houston, Texas

  • University of Utah / Primary Children's Hospital

    Salt Lake City, Utah

Showing 40 of 116 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.